Clinical Trial Update: A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the safety and tolerability of MT-125 in patients with glioblastoma. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• MT-125 (MT-125)

Snippet

Sponsor: Myosin Therapeutics Inc. | Conditions: Glioblastoma (GBM) | Phase 1, Phase 2 | Status: RECRUITING